Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study

Lexeo Therapeutics Inc. (NASDAQ:LXEO) on Monday announced positive interim results from its ongoing HEROIC-PKP2 Phase 1/2 trial evaluating LX2020 in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM) and outlined plans to launch a pivotal study in late 2027. PKP2-ACM is an inherited heart muscle condition caused by a change, or variant, in the PKP2 gene. The clinical-stage genetic medicine company…

Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study

Lexeo Therapeutics Inc. (NASDAQ:LXEO) has announced positive interim results from its HEROIC-PKP2 Phase 1/2 trial evaluating LX2020 in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The high-dose cohort of the study showed an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) from baseline, with six of seven patients experiencing improvement.

Cardiac MRIs also revealed stabilized or improved right ventricular function in most high-dose patients. The safety profile of LX2020 was generally favorable, with no discontinuations or clinically significant complement activation reported. Lexeo expects to finalize its pivotal study design and start the trial in late 2027, with its cash runway extending into 2028.

Brief written by urgent.news from Benzinga's own syndicated text. Machine-written — may contain errors; check the original before relying on it.

Read the original at benzinga.com →

More in Finance & Markets

More from Monday 16 November →